

Report bieżący ESPI_17_2024CURRENT REPORT 18/2024

May 27, 2024

Conclusion of funding agreement with the National Centre for Research and Development

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("**Company**") informs that on May 27, 2024, a funding agreement ("Agreement") was concluded with the National Centre for Research and Development ("NCBR") for the Company's phased project titled "New targeted therapy for tumors with MTAP gene deletion - Phase II" ("Phased Project"). The Agreement was concluded as part of the National Centre for Research and Development's SMART Pathway - Phased Projects competition, which enables obtaining funding for the implementation of Phase II of projects selected for funding based on the 2014-2020 perspective regulations under the Smart Growth Operational Programme 2014-2020 (SG OP), sub-measure 1.1.1 or measure 1.2. (research and development projects).

The Phased Project is subject to the Company's project with the funding agreement number: POIR.01.01.01-00-0638/18-00 titled: "New targeted therapy for tumors with MTAP gene deletion" ("Project"), aimed at the development and implementation of a next-generation oncology drug candidate characterized at the level of Phase I clinical trial. This candidate is a targeted therapy based on the phenomenon of synthetic lethality in tumors with MTAP deletion. As MTAP deletion is one of the most common genetic alterations found in human cancers, this gives hope for creating a targeted therapy for a significant population of cancer patients (up to 15%).

Ryvu is utilizing this mechanism in the implementation of the project for MTA-cooperative inhibitors of PRMT5 protein activity, with the selection of a preclinical candidate planned for 2024.

The Phased Project includes preclinical development and Phase I clinical study. The total funding in the form of a grant may amount to a maximum of PLN 10.28 million, which constitutes approximately 45% of the eligible costs of the Phased Project. The execution

period for the Phased Project is up to 50 months, with the Agreement allowing for changes to the schedule. The funding will be disbursed in tranches, according to the schedule specified in the Agreement.

Under the Agreement, the Company has committed to implementing the results of the Project, i.e., the results of the R&D work, within 3 years of its completion, either by incorporating the results into its own business activities, granting a license to use the rights to the R&D results, or selling the rights to the results to the third party on market terms.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Art. 17.1 of MAR

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board